TP53 and B-cell chronic lymphocytic leukemia: TP53 mutations are independently associated with worse progression-free survival (PFS) and OS in the setting of first-line CIT6 and have been incorporated into the recently published CLL-International Prognostic Index (CLL-IPI)19.